Follow
Pascal Schulthess
Pascal Schulthess
Hubrecht Institute, Utrecht, The Netherlands
Verified email at hubrecht.eu - Homepage
Title
Cited by
Cited by
Year
Signal integration by the CYP1A1 promoter — a quantitative study
P Schulthess, A Löffler, S Vetter, L Kreft, M Schwarz, A Braeuning, ...
Nucleic Acids Research 43 (11), 5318-5330, 2015
382015
Computer-assisted curation of a human regulatory core network from the biological literature
P Thomas, P Durek, I Solt, B Klinger, F Witzel, P Schulthess, Y Mayer, ...
Bioinformatics 31 (8), 1258-1266, 2015
182015
Outside‐in systems pharmacology combines innovative computational methods with high‐throughput whole vertebrate studies
P Schulthess, RC van Wijk, EHJ Krekels, JWT Yates, HP Spaink, ...
CPT: Pharmacometrics & Systems Pharmacology 7 (5), 285-287, 2018
172018
Frequency‐domain response analysis for quantitative systems pharmacology models
P Schulthess, TM Post, J Yates, PH van der Graaf
CPT: Pharmacometrics & Systems Pharmacology, 2017
92017
Optimization of Cancer Treatment in the Frequency Domain
P Schulthess, V Rottschäfer, JWT Yates, PH van der Graaf
The AAPS journal 21 (6), 106, 2019
42019
Characterization of the pharmacokinetic and pharmacodynamic profile of apraglutide, a glucagon-like peptide-2 analog, in healthy volunteers
F Bolognani, AC Kruithof, P Schulthess, M Machacek, ML de Kam, ...
Journal of Pharmacology and Experimental Therapeutics 386 (2), 129-137, 2023
32023
From reaction networks to information flow—Using modular response analysis to track information in signaling networks
P Schulthess, N Blüthgen
Methods in enzymology 500, 397-409, 2011
32011
The pharmacokinetic and pharmacodynamic relationship between apraglutide and citrulline: a randomized, placebo-controlled, double-blind study in healthy volunteers
F Bolognani, P Gal, M Moerland, A Kruithof, M van Gent, P Schulthess, ...
Clinical Nutrition ESPEN 40, 413-414, 2020
22020
Su559 POPULATION MODEL CONFIRMS PREDICTABLE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILE FOR APRAGLUTIDE-DATA FROM TWO RANDOMIZED PHASE 1 STUDIES
F Bolognani, M Machacek, A Kruithof, ML de Kam, K Bergmann, ...
Gastroenterology 160 (6), S-738, 2021
12021
P7. 09: Population Model Confirms Predictable Pharmacokinetic (PK) And Pharmacodynamic (PD) Profile for Apraglutide: Data From Two Randomized Phase 1 Studies
F Bolognani, M Machacek, A Kruithof, M de Kam, K Bergmann, ...
Transplantation 106 (9S), S544, 2022
2022
Thermodynamic modeling explains the regulation of CYP1A1 expression in the liver
P Schulthess
Humboldt-Universität zu Berlin, Lebenswissenschaftliche Fakultät, 2016
2016
Signal integration by the CYP1A1 promoter-a quantitative study
A Braeuning, P Schulthess, M Schwarz, N Bluethgen
FEBS JOURNAL 282, 80-80, 2015
2015
A quantitative study of dual signal integration by the CYP1A1 promoter
P Schulthess, A Loeffler, S Vetter, L Kreft, M Schwarz, A Braeuning, ...
FEBS JOURNAL 282, 81-81, 2015
2015
Cooperativity Between Aryl Hydrocarbon Receptor and beta-catenin Binding Sites in CYP1A1 Induction
P Schulthess, A Braeuning, A Loeffler, M Schwarz, N Bluethgen
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 386, S75-S75, 2013
2013
Interactions of signaling through the aryl hydrocarbon receptor and the β-catenin pathway in the regulation of CYP1A1 expression
A Braeuning, P Schulthess, A Löffler, N Blüthgen, M Schwarz
Toxicology Letters, S170, 2013
2013
Population Approach Group Europe Population Approach Group Europe
P Schulthess
The system can't perform the operation now. Try again later.
Articles 1–16